Overview

Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants

Status:
Completed
Trial end date:
2015-06-24
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to characterize the absorption and metabolic pathways of JNJ-63623872, and the excretion of the compound and its metabolites, after single oral dosing of 14C-JNJ-63623872 in healthy adult male participants.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Cilag N.V./S.A.